FREE Webinar

Tuesday, April 27, 2021
2:30 - 3:30 PM, Eastern Time

Register Now

Chimeric antigen receptor (CAR) T cells hold great promise for targeting and fighting cancer. However, their efficacy in solid tumors has been below expectations, as the tumor microenvironment (TME) limits their infiltration and produces a range of immune-inhibitory molecules to deactivate T cells. Researchers are developing new strategies to enhance CAR-T cell therapy for solid tumors by disrupting the TME and promoting T cell persistence. In this webinar brought to you by IsoPlexis, Katie McKenna will discuss how she uses CAR-T cells in combination with mesenchymal stromal cells that deliver engineered adenoviruses to stimulate the immune response in the TME.

Topics to be covered

  • Targeting non-small cell lung cancer using a cell carrier system to deliver an oncolytic and immunostimulatory adenovirus
  • Efficacy of oncolytic virotherapy in 3D cell culture and in vivo
  • Assessing T cell functionality...

Register Now

Meet the speaker

Katie McKenna, PhD
Postdoctoral Fellow
Center for Cell and Gene Therapy
Baylor College of Medicine
Texas Children’s Hospital
Methodist Hospital

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!